Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae | Zendy

B. Siquier | Zendy; J. Emilio Sánchez-Álvarez | Zendy; Elena García-Méndez | Zendy; Miguel Sabrià | Zendy; Jesús Francisco Santos Santos | Zendy; Román Pallarés | Zendy; Monique Twynholm | Zendy; Rafael Dal−Ré | Zendy

Open Access

Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae

Author(s) -

B. Siquier,

J. Emilio Sánchez-Álvarez,

Elena García-Méndez,

Miguel Sabrià,

Jesús Francisco Santos Santos,

Román Pallarés,

Monique Twynholm,

Rafael Dal−Ré

Publication year - 2006

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dki480

Subject(s) - amoxicillin , medicine , population , penicillin , pneumonia , streptococcus pneumoniae , antibacterial agent , clavulanic acid , community acquired pneumonia , antibiotics , gastroenterology , microbiology and biotechnology , biology , environmental health

This randomized, double-blind, non-inferiority trial evaluated the efficacy and safety of pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg twice daily versus amoxicillin/clavulanate 875/125 mg three times daily, both given orally for 7 or 10 days, in the treatment of adults with community-acquired pneumonia in Spain, a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research